{"title":"日本透析患者对 COVID-19 加强免疫的细胞和体液免疫反应。","authors":"Ayumi Yoshifuji, Masataro Toda, Emi Oyama, Tetsuo Nakayama, Setsuko Mise-Omata, Kan Kikuchi, Mamoru Yoshizawa, Naohiko Kato, Haruki Wakai, Kiyoto Koibuchi, Kohkichi Morimoto, Yoshifumi Uwamino, Ho Namkoong, Ayako Shibata, Kaoru Wakabayashi, Motoko Fujino, Motoaki Komatsu, Naoki Mochizuki, Norihiko Kondo, Akihiko Yoshimura, Naoki Hasegawa, Munekazu Ryuzaki","doi":"10.1007/s10157-024-02477-8","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Dialysis patients are susceptible to developing severe coronavirus disease 2019 (COVID-19) due to hypoimmunity. Antibody titers against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) after the primary vaccinations are lower in hemodialysis (HD) patients than in healthy individuals. This study aimed to evaluate the effect of a SARS-CoV-2 booster vaccination in HD and peritoneal dialysis (PD) patients based on antibody titers and cellular and humoral immunity.</p><p><strong>Methods: </strong>Participants of the control, HD, and PD groups were recruited from 12 facilities. SARS-CoV-2 antigen-specific cytokine and IgG-antibody levels were measured. Regulatory T cells and memory B cells were counted using flow cytometry at 6 months after primary vaccination with BNT162b2 and 3 weeks after the booster vaccination in HD and PD patients and compared with those of a control group.</p><p><strong>Results: </strong>Booster vaccination significantly enhanced the levels of antibodies, cytokines, and memory B cells in three groups. The HD group showed significantly higher levels of IgG-antibodies, IL-1β, IL-2, IL-4, IL-17, and memory B cells than those in the control group at 3 weeks after the booster dose. The PD group tended to show similar trends to HD patients but had similar levels of IgG-antibodies, cytokines, and memory B cells to the control group.</p><p><strong>Conclusions: </strong>HD patients had significantly stronger cellular and humoral immune responses than the control 3 weeks after the booster dose. Our findings will help in developing better COVID-19 vaccination strategies for HD and PD patients.</p>","PeriodicalId":10349,"journal":{"name":"Clinical and Experimental Nephrology","volume":" ","pages":"674-682"},"PeriodicalIF":2.2000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Cellular and humoral immune responses to COVID-19 booster vaccination in Japanese dialysis patients.\",\"authors\":\"Ayumi Yoshifuji, Masataro Toda, Emi Oyama, Tetsuo Nakayama, Setsuko Mise-Omata, Kan Kikuchi, Mamoru Yoshizawa, Naohiko Kato, Haruki Wakai, Kiyoto Koibuchi, Kohkichi Morimoto, Yoshifumi Uwamino, Ho Namkoong, Ayako Shibata, Kaoru Wakabayashi, Motoko Fujino, Motoaki Komatsu, Naoki Mochizuki, Norihiko Kondo, Akihiko Yoshimura, Naoki Hasegawa, Munekazu Ryuzaki\",\"doi\":\"10.1007/s10157-024-02477-8\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Dialysis patients are susceptible to developing severe coronavirus disease 2019 (COVID-19) due to hypoimmunity. Antibody titers against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) after the primary vaccinations are lower in hemodialysis (HD) patients than in healthy individuals. This study aimed to evaluate the effect of a SARS-CoV-2 booster vaccination in HD and peritoneal dialysis (PD) patients based on antibody titers and cellular and humoral immunity.</p><p><strong>Methods: </strong>Participants of the control, HD, and PD groups were recruited from 12 facilities. SARS-CoV-2 antigen-specific cytokine and IgG-antibody levels were measured. Regulatory T cells and memory B cells were counted using flow cytometry at 6 months after primary vaccination with BNT162b2 and 3 weeks after the booster vaccination in HD and PD patients and compared with those of a control group.</p><p><strong>Results: </strong>Booster vaccination significantly enhanced the levels of antibodies, cytokines, and memory B cells in three groups. The HD group showed significantly higher levels of IgG-antibodies, IL-1β, IL-2, IL-4, IL-17, and memory B cells than those in the control group at 3 weeks after the booster dose. The PD group tended to show similar trends to HD patients but had similar levels of IgG-antibodies, cytokines, and memory B cells to the control group.</p><p><strong>Conclusions: </strong>HD patients had significantly stronger cellular and humoral immune responses than the control 3 weeks after the booster dose. Our findings will help in developing better COVID-19 vaccination strategies for HD and PD patients.</p>\",\"PeriodicalId\":10349,\"journal\":{\"name\":\"Clinical and Experimental Nephrology\",\"volume\":\" \",\"pages\":\"674-682\"},\"PeriodicalIF\":2.2000,\"publicationDate\":\"2024-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical and Experimental Nephrology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s10157-024-02477-8\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/3/8 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"UROLOGY & NEPHROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Experimental Nephrology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10157-024-02477-8","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/3/8 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景：透析患者由于免疫力低下，很容易患上严重冠状病毒病2019（COVID-19）。血液透析（HD）患者初次接种严重急性呼吸系统综合征冠状病毒-2（SARS-CoV-2）后的抗体滴度低于健康人。本研究旨在根据抗体滴度、细胞免疫和体液免疫评估血液透析和腹膜透析（PD）患者接种 SARS-CoV-2 加强型疫苗的效果：方法： 从 12 家医院招募了对照组、HD 组和 PD 组的参与者。测量 SARS-CoV-2 抗原特异性细胞因子和 IgG 抗体水平。在 HD 和 PD 患者接种 BNT162b2 初免 6 个月后和加强免疫 3 周后，使用流式细胞术对调节性 T 细胞和记忆性 B 细胞进行计数，并与对照组进行比较：结果：加强免疫明显提高了三组患者的抗体、细胞因子和记忆 B 细胞水平。HD组在加强接种3周后的IgG抗体、IL-1β、IL-2、IL-4、IL-17和记忆B细胞水平明显高于对照组。PD组的趋势与HD患者相似，但IgG抗体、细胞因子和记忆B细胞的水平与对照组相似：结论：HD 患者在加强剂量 3 周后的细胞和体液免疫反应明显强于对照组。我们的研究结果将有助于为 HD 和 PD 患者制定更好的 COVID-19 疫苗接种策略。
Cellular and humoral immune responses to COVID-19 booster vaccination in Japanese dialysis patients.
Background: Dialysis patients are susceptible to developing severe coronavirus disease 2019 (COVID-19) due to hypoimmunity. Antibody titers against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) after the primary vaccinations are lower in hemodialysis (HD) patients than in healthy individuals. This study aimed to evaluate the effect of a SARS-CoV-2 booster vaccination in HD and peritoneal dialysis (PD) patients based on antibody titers and cellular and humoral immunity.
Methods: Participants of the control, HD, and PD groups were recruited from 12 facilities. SARS-CoV-2 antigen-specific cytokine and IgG-antibody levels were measured. Regulatory T cells and memory B cells were counted using flow cytometry at 6 months after primary vaccination with BNT162b2 and 3 weeks after the booster vaccination in HD and PD patients and compared with those of a control group.
Results: Booster vaccination significantly enhanced the levels of antibodies, cytokines, and memory B cells in three groups. The HD group showed significantly higher levels of IgG-antibodies, IL-1β, IL-2, IL-4, IL-17, and memory B cells than those in the control group at 3 weeks after the booster dose. The PD group tended to show similar trends to HD patients but had similar levels of IgG-antibodies, cytokines, and memory B cells to the control group.
Conclusions: HD patients had significantly stronger cellular and humoral immune responses than the control 3 weeks after the booster dose. Our findings will help in developing better COVID-19 vaccination strategies for HD and PD patients.
期刊介绍：
Clinical and Experimental Nephrology is a peer-reviewed monthly journal, officially published by the Japanese Society of Nephrology (JSN) to provide an international forum for the discussion of research and issues relating to the study of nephrology. Out of respect for the founders of the JSN, the title of this journal uses the term “nephrology,” a word created and brought into use with the establishment of the JSN (Japanese Journal of Nephrology, Vol. 2, No. 1, 1960). The journal publishes articles on all aspects of nephrology, including basic, experimental, and clinical research, so as to share the latest research findings and ideas not only with members of the JSN, but with all researchers who wish to contribute to a better understanding of recent advances in nephrology. The journal is unique in that it introduces to an international readership original reports from Japan and also the clinical standards discussed and agreed by JSN.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
